p38alpha and S1P-dependent SREBP2 activation by the SAM-competitive EZH2 inhibitor GSK343 limits its anticancer activity but creates a druggable vulnerability in hepatocellular carcinoma

Name: p38alpha and S1P-dependent SREBP2 activation by the SAM-competitive EZH2 inhibitor GSK343 limits its anticancer activity but creates a druggable vulnerability in hepatocellular carcinoma
Creator: 暂无描述
License: 暂无描述

NIAID Data Ecosystem2026-03-11 收录

下载链接：

https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE129204

下载链接

链接失效反馈

官方服务：

资源简介：

This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

创建时间：

2019-11-17